Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that […]
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and.
Cytokinetics (NASDAQ:CYTK – Get Rating) and Kezar Life Sciences (NASDAQ:KZR – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership. Risk and Volatility Cytokinetics has a beta of 0.8, indicating […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 12,500 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $37.41, for a total transaction of $467,625.00. Following the sale, the chief executive officer now owns 441,058 shares in the company, […]
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) have earned an average recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12 month price […]